• Je něco špatně v tomto záznamu ?

Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure

I. Netuka, T. Kvasnička, J. Kvasnička, I. Hrachovinová, P. Ivák, F. Mareček, J. Bílková, I. Malíková, M. Jančová, J. Malý, P. Sood, KS. Sundareswaran, JM. Connors, MR. Mehra,

. 2016 ; 35 (7) : 860-7. [pub] 20160531

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025348

BACKGROUND: Contemporary continuous-flow left ventricular assist devices (CF-LVADs) are associated with degradation of von Willebrand factor (vWF) high-molecular-weight multimers (HMWMs), a critical factor supporting platelet function. We hypothesized that the HeartMate 3 fully magnetically levitated LVAD, designed to reduce circulatory shear stress, favorably influences these hemostatic parameters. METHODS: Fifteen consecutive HeartMate 3 LVAD patients were compared with 11 consecutive HeartMate II controls. Serial plasma samples were collected pre-implant and on Days 2, 7, 30 and 45 post-operatively. Changes in vWF HMWMs were evaluated by 2 independent, study-blind hematologists and confirmed using densitometry-based computerized software. Ristocetin cofactor (RiCO) and vWF antigen (vWF Ag) were measured using standard protocols with enzyme-linked immunosorbent assay. RESULTS: HeartMate 3 patients and HeartMate II controls had a mean age of 67.3 ± 1.4 and 52.8 ± 2.5 years, respectively (INTERMACS Profiles 2 to 4 in 93.3% and 91%, respectively). HeartMate 3 group demonstrated a significantly greater preservation of HMWMs compared with the HeartMate II group, with the most prominent decrease occurring by Day 2 post-operatively and sustained through 45 days (71.94% vs 31.16%, p = 0.001). Laboratory values (normalized to baseline) for RiCO activity, vWF Ag and RiCO:vWF Ag ratio remained in the functional range with no statistically significant differences observed between groups. CONCLUSION: The HeartMate 3 LVAD is associated with enhanced hemocompatibility compared with the HeartMate II LVAD, as demonstrated by the improved preservation of vWF HMWMs, In contrast, effects on HMWM degradation appeared to be dissociated from functional attributes. Further confirmation of these findings in randomized clinical trials is warranted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025348
003      
CZ-PrNML
005      
20180718112545.0
007      
ta
008      
180709s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.healun.2016.05.019 $2 doi
035    __
$a (PubMed)27435529
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Netuka, Ivan $u Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Second Department of Surgery, First Faculty of Medicine, Charles University of Prague, Prague, Czech Republic. Electronic address: ivan.netuka@ikem.cz.
245    10
$a Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure / $c I. Netuka, T. Kvasnička, J. Kvasnička, I. Hrachovinová, P. Ivák, F. Mareček, J. Bílková, I. Malíková, M. Jančová, J. Malý, P. Sood, KS. Sundareswaran, JM. Connors, MR. Mehra,
520    9_
$a BACKGROUND: Contemporary continuous-flow left ventricular assist devices (CF-LVADs) are associated with degradation of von Willebrand factor (vWF) high-molecular-weight multimers (HMWMs), a critical factor supporting platelet function. We hypothesized that the HeartMate 3 fully magnetically levitated LVAD, designed to reduce circulatory shear stress, favorably influences these hemostatic parameters. METHODS: Fifteen consecutive HeartMate 3 LVAD patients were compared with 11 consecutive HeartMate II controls. Serial plasma samples were collected pre-implant and on Days 2, 7, 30 and 45 post-operatively. Changes in vWF HMWMs were evaluated by 2 independent, study-blind hematologists and confirmed using densitometry-based computerized software. Ristocetin cofactor (RiCO) and vWF antigen (vWF Ag) were measured using standard protocols with enzyme-linked immunosorbent assay. RESULTS: HeartMate 3 patients and HeartMate II controls had a mean age of 67.3 ± 1.4 and 52.8 ± 2.5 years, respectively (INTERMACS Profiles 2 to 4 in 93.3% and 91%, respectively). HeartMate 3 group demonstrated a significantly greater preservation of HMWMs compared with the HeartMate II group, with the most prominent decrease occurring by Day 2 post-operatively and sustained through 45 days (71.94% vs 31.16%, p = 0.001). Laboratory values (normalized to baseline) for RiCO activity, vWF Ag and RiCO:vWF Ag ratio remained in the functional range with no statistically significant differences observed between groups. CONCLUSION: The HeartMate 3 LVAD is associated with enhanced hemocompatibility compared with the HeartMate II LVAD, as demonstrated by the improved preservation of vWF HMWMs, In contrast, effects on HMWM degradation appeared to be dissociated from functional attributes. Further confirmation of these findings in randomized clinical trials is warranted.
650    _2
$a ELISA $7 D004797
650    12
$a srdeční selhání $7 D006333
650    _2
$a podpůrné srdeční systémy $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mechanický stres $7 D013314
650    _2
$a von Willebrandova nemoc $7 D014842
650    _2
$a von Willebrandův faktor $7 D014841
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kvasnička, Tomáš $u Thrombotic Centre and Central Hematology Laboratory, Institute of Medical Biochemistry and Laboratory Diagnostics of the General University Hospital and First Faculty of Medicine of Charles University of Prague, Prague, Czech Republic.
700    1_
$a Kvasnička, Jan $u Thrombotic Centre and Central Hematology Laboratory, Institute of Medical Biochemistry and Laboratory Diagnostics of the General University Hospital and First Faculty of Medicine of Charles University of Prague, Prague, Czech Republic.
700    1_
$a Hrachovinová, Ingrid $u NRL for Hemostasis, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Ivák, Peter $u Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Third Faculty of Medicine, Charles University of Prague,Prague, Czech Republic.
700    1_
$a Mareček, František $u NRL for Hemostasis, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Bílková, Jana $u Thrombotic Centre and Central Hematology Laboratory, Institute of Medical Biochemistry and Laboratory Diagnostics of the General University Hospital and First Faculty of Medicine of Charles University of Prague, Prague, Czech Republic.
700    1_
$a Malíková, Ivana $u Thrombotic Centre and Central Hematology Laboratory, Institute of Medical Biochemistry and Laboratory Diagnostics of the General University Hospital and First Faculty of Medicine of Charles University of Prague, Prague, Czech Republic.
700    1_
$a Jančová, Michaela $u Laboratory Methods, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Malý, Jiří $u Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Sood, Poornima $u St. Jude Medical, Minneapolis, Minnesota, USA.
700    1_
$a Sundareswaran, Kartik S $u St. Jude Medical, Minneapolis, Minnesota, USA.
700    1_
$a Connors, Jean M $u Department of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
700    1_
$a Mehra, Mandeep R $u Heart and Vascular Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
773    0_
$w MED00002704 $t The Journal of heart and lung transplantation the official publication of the International Society for Heart Transplantation $x 1557-3117 $g Roč. 35, č. 7 (2016), s. 860-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27435529 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180718112845 $b ABA008
999    __
$a ok $b bmc $g 1317479 $s 1022269
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 35 $c 7 $d 860-7 $e 20160531 $i 1557-3117 $m The Journal of heart and lung transplantation $n J Heart Lung Transplant $x MED00002704
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace